Novartis acquired Spinifex for $200M upfront plus undisclosed clinical development and regulatory milestone payments (estimated up-to ~$500M, total ~$700M). EMA401 was a peripheral AT2R antagonist for neuropathic pain. Novartis later discontinued EMA401 development.